OpenLB
Open Library of Bioscience
Advanced Search
Frontiers in endocrinology
2024;15 1322731.

Clinical features combined with ultrasound characteristics to predict TERT promoter mutations in papillary thyroid carcinoma: a single-center study over the past 5 years.

Yan Hu, Shangyan Xu, Lei Dong, Zuxian Pan, Lu Zhang, Weiwei Zhan
Author Information
  1. Yan Hu: Department of Ultrasound, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  2. Shangyan Xu: Department of Ultrasound, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  3. Lei Dong: Department of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  4. Zuxian Pan: Department of Ultrasound, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  5. Lu Zhang: Department of Ultrasound, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  6. Weiwei Zhan: Department of Ultrasound, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
PMID: 38562417 DOI: 10.3389/fendo.2024.1322731

Abstract

Purpose: Telomerase reverse transcriptase (TERT) has been reported in papillary thyroid carcinoma (PTC). This study aimed to investigate the correlation of TERT promoter mutations with clinical and ultrasound (US) features in PTC and to develop a model to predict TERT promoter mutations.
Methods: Preoperative US images, postoperative pathological features, and TERT promoter mutation information were evaluated in 365 PTC patients confirmed by surgery. Univariate and multivariate factor analyses were performed to identify risk factors for TERT promoter mutations. A predictive model was established to assess the clinical predictive value.
Results: Of the 365 patients with PTC (498 nodules), the number of those with TERT promoter mutations was 67 cases (75 nodules), and the number of those without mutations was 298 cases (423 nodules). The median age was 40 years in the wild-type group and 60 years in the mutant group. Male patients made up 35.82% of the mutant group and 22.82% of the wild-type group. Multivariate analysis revealed that the independent risk factors associated with the occurrence of TERT promoter mutation in PTC were as follows: older age (odds ratio (OR) = 1.07; = 0.002), maximum diameter of ≥ 10 mm (OR = 3.94; < 0.0001), unilateral (OR = 4.15; < 0.0001), multifocal (OR = 7.69; < 0.0001), adjacent to the thyroid capsule (OR = 1.94; = 0.044), and accompanied by other benign nodules (OR = 1.94, = 0.039). A predictive model was established, and the area under the curve (AUC) of the receiver operating characteristic was 0.839. TERT promoter mutations were associated with high-risk US and clinical features compared with the wild-type group.
Conclusion: TERT promoter mutations were associated with older ages. They were also found to be multifocal, with a maximum diameter of ≥ 10 mm, unilateral, adjacent to the thyroid capsule, and accompanied by other benign nodules. The predictive model was of high diagnostic value.

Keywords

TERT molecular marker papillary thyroid cancer thyroid nodule ultrasound

References

  1. J Clin Invest. 2016 Mar 1;126(3):1052-66 [PMID: 26878173]
  2. Endocr Rev. 2019 Dec 1;40(6):1573-1604 [PMID: 31322645]
  3. J Clin Endocrinol Metab. 2014 May;99(5):E754-65 [PMID: 24476079]
  4. Endocrine. 2020 Jan;67(1):44-57 [PMID: 31655978]
  5. Clin Endocrinol (Oxf). 2016 Aug;85(2):299-305 [PMID: 26732020]
  6. J Clin Med. 2021 May 18;10(10): [PMID: 34070093]
  7. JAMA Oncol. 2017 Feb 01;3(2):202-208 [PMID: 27581851]
  8. Front Endocrinol (Lausanne). 2023 Jul 03;14:1156999 [PMID: 37465126]
  9. Clin Endocrinol (Oxf). 2022 Jul;97(1):106-115 [PMID: 35343605]
  10. Thyroid. 2016 Jul;26(7):901-10 [PMID: 27184112]
  11. PLoS One. 2016 Apr 11;11(4):e0153319 [PMID: 27064992]
  12. Thyroid. 2011 Feb;21(2):125-34 [PMID: 21186939]
  13. Science. 2013 Feb 22;339(6122):957-9 [PMID: 23348506]
  14. Cell. 2014 Oct 23;159(3):676-90 [PMID: 25417114]
  15. Science. 2013 Feb 22;339(6122):959-61 [PMID: 23348503]
  16. Sci Adv. 2023 Sep;9(35):eadg7125 [PMID: 37647391]
  17. Endocr Relat Cancer. 2016 Oct;23(10):813-23 [PMID: 27528624]
  18. Clin Endocrinol (Oxf). 2021 Nov;95(5):790-799 [PMID: 34322882]
  19. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  20. Endocr Connect. 2023 Jun 1;: [PMID: 37310413]
  21. Cancers (Basel). 2022 Oct 08;14(19): [PMID: 36230856]
  22. Clin Endocrinol (Oxf). 2016 Aug;85(2):283-90 [PMID: 26667986]
  23. Cancer. 2016 May 1;122(9):1370-9 [PMID: 26969876]
  24. Lancet Diabetes Endocrinol. 2022 Apr;10(4):264-272 [PMID: 35271818]
  25. Nat Commun. 2021 Oct 18;12(1):6058 [PMID: 34663816]
  26. Clin Endocrinol (Oxf). 2019 Dec;91(6):834-841 [PMID: 31441082]
  27. Endocrine. 2017 Aug;57(2):234-240 [PMID: 28616852]
  28. J Clin Oncol. 2014 Sep 1;32(25):2718-26 [PMID: 25024077]
  29. Ann Surg. 2020 Mar;271(3):e21-e93 [PMID: 32079830]
  30. Cancer Lett. 2020 Nov 28;493:1-9 [PMID: 32768523]
  31. Endocrine. 2020 May;68(2):349-357 [PMID: 32026251]

MeSH Term

Humans
Male
Adult
Thyroid Cancer, Papillary
Thyroid Neoplasms
Carcinoma, Papillary
Promoter Regions, Genetic
Mutation
Telomerase

Chemicals

TERT protein, human
Telomerase
Journal Article
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0TERTpromoter=mutations0thyroidORPTCnodulesgroupfeaturesmodelpredictivepapillaryclinicalultrasoundUSpatientsyearswild-typeassociated194<0001studypredictmutation365riskfactorsestablishedvaluenumbercasesagemutant82%oldermaximumdiameter≥10mmunilateralmultifocaladjacentcapsuleaccompaniedbenignPurpose:TelomerasereversetranscriptasereportedcarcinomaaimedinvestigatecorrelationdevelopMethods:PreoperativeimagespostoperativepathologicalinformationevaluatedconfirmedsurgeryUnivariatemultivariatefactoranalysesperformedidentifyassessResults:4986775without298423median4060Malemade3522Multivariateanalysisrevealedindependentoccurrencefollows:oddsratio070023415769044039areacurveAUCreceiveroperatingcharacteristic839high-riskcomparedConclusion:agesalsofoundhighdiagnosticClinicalcombinedcharacteristicscarcinoma:single-centerpast5molecularmarkercancernodule

Similar Articles

Cited By